Tripos International

What Tripos International does

Tripos International, operating today under the Certara brand (Certara USA, Inc.; NASDAQ: CERT), is a drug development solutions provider founded in 1979 and headquartered in St. Louis, Missouri. The company delivers a vertically integrated platform spanning the full drug development lifecycle — from discovery through preclinical, clinical, regulatory submission, and market access — combining proprietary scientific software with professional services to biopharmaceutical companies and contract research organizations (CROs).

The company's core technology rests on predictive simulation, data-driven biosimulation, quantitative systems pharmacology (QSP), physiologically-based pharmacokinetic (PBPK) modeling, and AI tailored for life sciences. Its software portfolio includes 12+ proprietary platforms: Phoenix (PK/PD/toxicokinetic analysis), Simcyp (PBPK modeling), Pinnacle 21 (regulatory data standardization), D360 (scientific informatics), Certara IQ (QSP), Certara.AI (AI platform), CoAuthor (GenAI regulatory writing), GlobalSubmit (eCTD submission publishing), BaseCase (value communications), SEND Explorer (nonclinical data visualization), Chemaxon (cheminformatics), and Non-Animal Navigator (AI for non-animal regulatory strategies). These tools are complemented by professional services in modeling and simulation, biometrics and data science, drug development support, regulatory strategy, real-world evidence and market access, and therapeutic specialty consulting.

Certara operates a dual revenue model: subscription-based licensing of its proprietary software platforms and fee-based professional and consulting services. Distribution is primarily direct enterprise sales to three customer segments — emerging and growth-stage biotechs, large pharmaceutical companies, and CROs — across 30+ countries, supported by a customer self-service portal, sales inquiry forms segmented by services and software, and a strategic partner ecosystem. The company employs 1,550+ people globally, including 440+ PhDs (over 28% of the workforce), and states that its customers have received 90% or more of all FDA novel drug approvals from 2014 through 2025, with its technology used in 100+ novel drug and 325 label claim approvals. Pricing is not publicly disclosed and is quote-based.

Name

Tripos International

Legal name

Certara USA, Inc.

Website

https://tripos.com

Company type

Public

Founded year

1979

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Tripos International (operating as Certara, NASDAQ: CERT) is a publicly traded drug development solutions provider offering proprietary scientific software (Phoenix, Simcyp, Pinnacle 21, Certara.AI, CoAuthor) and professional services across PK/PD modeling, biosimulation, regulatory submissions, and market access to biotech, large pharma, and CRO customers globally.

Ownership category

akta.pro rank

Product category

Drug Discovery Informatics

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Regulatory Information Management (RIM) & Submission Publishing Software (HLAGAJAL)

Keywords

• Drug discovery informatics
• Scientific informatics software
• Compound identification optimization
• Cheminformatics platform
• Molecular data analytics

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Software subscriptions and licensing: Recurring subscription-based licensing to proprietary software platforms (Phoenix, Pinnacle 21, Simcyp, D360, Certara.AI, CoAuthor, GlobalSubmit, BaseCase, SEND Explorer, Chemaxon, Non-Animal Navigator). BaseCase EULA indicates the application is licensed (not sold) and remains in effect as long as the Customer subscribes to the BaseCase Platform.
2. Professional and consulting services: Tailored services including modeling and simulation, biometrics and data science, drug development support, regulatory strategy, real-world evidence and market access, and therapeutic specialty consulting (oncology, pediatrics, rare diseases, etc.). Services are mapped to solutions across Regulatory, Discovery, Preclinical, Early Clinical, Late Clinical, and Market Access & Commercial.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Tripos International, operating through its Tripos Discovery Informatics brand, provides scientific informatics software for the identification and optimization of new chemical compounds with the potential to become drugs. Its D360 platform enables scientists to access, analyze, and visualize molecule and bioactivity data, complemented by Chemaxon cheminformatics tooling for chemical and biological intelligence and Phoenix PK/PD/TK modeling (inherited from the Pharsight acquisition). The offering is delivered alongside model-informed drug development, biosimulation, and drug development support services for pharmaceutical, biotechnology, and CRO customers.

Product overview

Certara operates a platform-plus-modules architecture for drug development. The Certara.AI platform underpins AI-driven capabilities, while a portfolio of specialized software modules — Phoenix® (PK/PD/TK analysis), Pinnacle 21® (data standardization), Simcyp® (PBPK modeling), D360™ (scientific informatics), SEND Explorer® (nonclinical data visualization), BaseCase® (value communications), GlobalSubmit™ (eCTD submissions), Chemaxon® (cheminformatics), CoAuthor™ (GenAI regulatory writing), and Certara IQ™ (quantitative systems pharmacology) — addresses each drug development phase. These software modules are complemented by professional services including Modeling and Simulation, Biometrics and Data Science, Drug Development Support, Regulatory Strategy, Real World Evidence and Market Access, and Therapeutic Specialities Centers of Excellence. Solution bundles (Regulatory, Discovery, Preclinical, Early Clinical, Late Clinical, Market Access & Commercial, and Strategic Leadership) tie the software and services together across the development lifecycle, with newer offerings such as Non-Animal Navigator™ and Bio Venture Catalyst extending the portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• Phoenix: Software platform for PK, PD, and toxicokinetic analysis and modeling.
• Pinnacle 21
• Certara IQ
• GlobalSubmit
• BaseCase
• SEND Explorer
• Simcyp
• D360
• Certara.AI
• CoAuthor
• Chemaxon

Products and services

• D360™ D360™ is a scientific informatics platform that enables scientists to access, analyze, and visualize molecule and bioactivity data to support drug discovery research for pharmaceutical and biotechnology R&D teams.
• Chemaxon® Chemaxon® is cheminformatics software that enhances scientific discovery with chemical and biological intelligence across drug discovery workflows for pharmaceutical and biotechnology customers.
• Phoenix® Phoenix® is pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) analysis and modeling software that supports drug development decision-making for pharmaceutical, biotechnology, and CRO customers.
• Modeling and Simulation Services Modeling and Simulation Services optimize drug development using predictive biosimulation and modeling to inform dosing, safety, and efficacy decisions for biotech, large pharma, and CRO customers.

Quantifiable outcome

• Technology used in 100+ novel drugs and 325 label claim approvals in lieu of clinical trials
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability10 records

Feature12 records

Partnerships

One partnership is on record.

• European Medicines Agency (EMA)majorStrategic or Co-development PartnerReappointed for an EMA contract, expanding opportunities to shape the future of real-world evidence for regulatory decision-making. The company's platforms are fully aligned with and used by global regulatory bodies, and the partnership supports regulatory strategy, real-world evidence, and market access workstreams across customer engagements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Veeva Systems: Veeva is a leading cloud software provider for life sciences with deep penetration across pharma R&D, regulatory (Vault RIM), clinical (Vault CDB/EDC), and commercial functions. It directly competes with Certara in regulatory submission and clinical data management software (Vault vs. Pinnacle 21/GlobalSubmit).
• Schrödinger: Schrödinger operates a physics-based computational platform plus AI/ML for molecular design and drug discovery, competing most directly with Certara's Chemaxon, D360, and Certara IQ offerings in cheminformatics and QSP.
• Dassault Systèmes (BIOVIA): Dassault's BIOVIA brand provides scientific informatics, molecular modeling, and laboratory informatics software to life sciences — directly overlapping with Certara's D360, Phoenix, and Chemaxon portfolios in discovery and preclinical informatics.
• Medidata Solutions (Dassault): Medidata's Rave Clinical Cloud and Synthetic Control Arm offerings overlap with Certara's clinical pharmacology and biosimulation services, especially in model-informed trial design and CDISC-standard data management.

Emerging players

• LabVantage Solutions: LabVantage is a LIMS and laboratory informatics provider competing in adjacent life sciences software categories; meaningful overlap with Certara's scientific informatics and data standardization capabilities, particularly for pharma labs.
• ArisGlobal: ArisGlobal provides life sciences R&D technology including regulatory information management, safety, and clinical platforms — directly competing with Certara's Pinnacle 21, GlobalSubmit, and CoAuthor offerings in the regulatory software stack.

Broad incumbents

• IQVIA: IQVIA is a global CRO and healthcare data analytics leader whose R&D services and technology platforms (e.g., E360, Rave) overlap with Certara's biometrics, clinical pharmacology, and regulatory service offerings, though IQVIA operates at much broader scale.
• ICON plc: ICON is one of the largest global CROs providing clinical research, biometric, and laboratory services to pharma — comparable in its drug development services portfolio to Certara's professional services arm, though less software-centric.
• Thermo Fisher Scientific (Patheon/CDMO): Thermo Fisher's PPD clinical research services and scientific instruments/lab informatics portfolio address overlapping pharma R&D customers, though Thermo Fisher operates across a much broader life sciences value chain.
• Charles River Laboratories: Charles River provides preclinical CRO services and scientific informatics, overlapping with Certara's preclinical modeling (Phoenix) and discovery (D360) offerings on the wet-lab plus software boundary.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/certara
• YouTubeyoutube.com/user/CertaraLP
• Facebookfacebook.com/certaralp
• LinkedInlinkedin.com/company/tripos

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tripos International